Beijing Ensign Trading Co, Ltd, fo‍‍unded in 1999, mainly‍‍ Promotes  medical devices in the Chinese market

 and Provides services., Our company is also committed to introducing the latest medical technology and 

equipment into China.

    The headquarter of our company locates at Beijing, We serve the leading medical institutions among the 

major cities and dedicate to provide the best medical services to patients and to create a beneficial research

 and development environment for doctors.

    Through telemedicine surgery and telemedicine consultation training doctors, The Spinal Cord Injury 

Reconstrution of Bladder System Medical Centers, which are located at Beijing and Shanghai, provide the 

professional training for medical workers and become the most trusted partner.

    Successfully developed by the famous British medical scientist Brindley and British company Finetech, the 

implantable sacral nerve root stimulation system was applied to clinical surgery in 1982 for the first time and 

had significant efficacy. Nowadays, with the constant improvement in subsequent clinical application, this 

product has been widely used in more than 40 countries including the United States, Britain, Germany, 

Holland, Brazil, Columbia Singapore etc. for more than 30 years.  In China, the first clinical patients has used 

the products for more than 10 years and this technology is highly recognized by the majority of doctors and 

patients.  Finetech-Medical company and In 2005, Finetech-Medical company and Beijing Ensign trading Co, 

ltd carried out the introduction of this product. Twelve years later, after the rigorous experimental testing and 

clinical verification, it is finally approved by People's Republic of China state food and Drug 

Administration (CFDA) and enter into China market to serve Chinese patients in August 2016. (in Mechanical 

injection: 20163212593-595) in 2005 to carry out the introduction of Chinese work through rigorous 

experimental testing and clinical verification, after 12 years and finally by the People's Republic of China state food and Drug Administration (CFDA) approval, in August 2016 to enter China market, service to Chinese 

patients (in Mechanical injection: 20163212593-595).